Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: A prospective cohort trial

Teresa R. Zembower, Kelly M. Maxwell, Robert B. Nadler, John Cashy, Marc H. Scheetz, Chao Qi, Anthony J. Schaeffer*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background: We evaluated the effectiveness of targeted antimicrobial prophylaxis in transrectal ultrasound guided prostate biopsy (TRUSP). Methods: A prospective, non-randomized cohort study was conducted. Rectal swab cultures plated on non-selective blood agar and on selective MacConkey agar supplemented with ciprofloxacin identified ciprofloxacin-susceptible and -resistant gram-negative bacteria (CS-GNB and CR-GNB). Patients with CS-GNB received ciprofloxacin while those with CR-GNB received directed prophylaxis. Infectious complications were defined clinically and microbiologically within 30 days after TRUSP. Data were derived at 7 and 30 days post procedure by questionnaires and electronic medical records. We hypothesized that there would be no difference in the infectious outcomes among the CS and CR groups. Results: From November 1, 2012 to March 31, 2015, 510 men completed the study; 430 (84.3%) had CS-GNB and 80 (15.7%) had CR-GNB. 484 (94.9%) completed the study per protocol, while 26 (5.1%) had an intention-to-treat (ITT) analysis. Of the 484, 475 (98.1%) had no infections, nine (1.9%) had infections, six of which (1.2%) were culture-proven (CP). The nine infections were as follows: five (1.0%) uncomplicated UTIs, one (0.2%) complicated UTI, and three (0.6%) urosepsis. One case of uncomplicated UTI and two cases of urosepsis were not CP, but were diagnosed clinically. ITT outcomes were similar. The infection rates were not statistically different between the CS-and CR-GNB patients (p-value = 0.314; 95% CI 0.8-3.3). The four patients with complicated UTIs or sepsis were hospitalized for a mean of 2.6 days and discharged without sequelae. Of the nine infections, three were antimicrobial prophylaxis failures (two ciprofloxacin and one amikacin); three were likely due to failure of the collection or processing of the rectal swab or increasing bacterial resistance between the time of swab collection and biopsy, and three developed clinical infections with no isolate recovered. Conclusions: Targeted antimicrobial prophylaxis follows the principles of antimicrobial stewardship and achieved a low rate of infectious complications with limited morbidity and no sequelae. This individualized method of prophylaxis may be widely applied. Further studies are needed to explore reasons for targeted prophylaxis failure and to determine comparative efficacy of non-ciprofloxacin-containing targeted prophylaxis regimens. Trial registration: ClinicalTrials.gov. NCT01659866. Registered 9 July 2012. First patient enrolled 1 November 2012.

Original languageEnglish (US)
Article number401
JournalBMC Infectious Diseases
Volume17
Issue number1
DOIs
StatePublished - Jun 7 2017

Keywords

  • Antibacterial agents
  • Biopsy
  • Infection
  • Urology

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: A prospective cohort trial'. Together they form a unique fingerprint.

  • Cite this